ASCO 2021 Updates on Safety and Efficacy Outcomes With Nivo+Ipi in P…

Hamid Emamekhoo

ASCO 2021 Updates on Real-World Outcomes in Patients With mRCC Recei…

Kayvan Zarrabi

2021 Updates on Advanced RCC: CLEAR and SWOG 1500 Targeted Therapy O…

UNC Lineberger Comprehensive Cancer Center

M. Milowsky

mRCC Case Study Panel Discussion: Management of Long-Term CPI irAEs …

Cleveland Clinic's 2021 Management of Checkpoint Inhibitor-Related Toxicity

A. Haddad, J. Ellsworth-Wolk, C. Calabrese

CheckMate-214 for mRCC: An Update on Efficacy, Activity and Safety o…

Camillo Porta

Immune CPIs as Mono and Combination Therapy for RCC: New 1L Strategi…

CECOG Academy

M. Schmidinger

2021 Updates in RCC: Surveying Data for SWOG 1500, Belzutifan, CLEAR…

Virtual West Oncology Conference

B. Somer

Sequencing Therapies for mRCC: Which Treatment to Select After Progr…

UNC Lineberger Comprehensive Cancer Center

T. Rose, M. Milowsky

2021 Updates in Targeted Therapies for mRCC: IO Combos, Assessing IM…

3rd Annual Atlanta Precision Oncology Symposium

T. Zhang

1L Treatment Approach in mRCC: How to Make an Appropriate Regimen Ch…

UNC Lineberger Comprehensive Cancer Center

T. Rose, M. Milowsky

Fox Chase Updates on mRCC: Surveying Options for 1L, 2L and Beyond

Fox Chase Cancer Center's Genitourinary Malignancies in the Time of COVID-19

M. Zibelman

Hot Topics: Recent Advances in the Diagnosis and Classification of R…

Derek B. Allison

ESMO 2021 5-Year Follow-Up Data From CheckMate 214: Ipi + Nivo vs. S…

Viktor Grünwald

ESMO 2021 Updates on GU Cancers: 5-Year Follow-Up in CheckMate 214 a…

LARVOL

B. McGregor, S. Gupta, D. Kilari

ASCO GU 2022 on Nivo + Cabo vs. Sunitinib for Advanced RCC: Final OS…

ASCO Genitourinary Cancers Symposium

T. Powles

Current Status of Adjuvant and Frontline Therapies for Advanced RCC

2022 West Oncology Conference

B. Rini